Le Lézard
Classified in: Health, Covid-19 virus
Subjects: SVY, TRI

Landmark New Publication: the Forgotten Biochemistry 101 of COVID-19


Legacy coronavirus biochemistry was overlooked that governs spike protein toxicity, key morbidities, risk factors and therapeutic responses

SALT LAKE CITY, April 22, 2024 /PRNewswire/ -- TrialSite News features a paper published today in Viruses (Basel), authored by an international team of researchers, including two fellows of their nations' academies of sciences (Colleen Aldous, senior author Wendy Hoy) and others who participated in Nobel prize-honored research (Thomas Borody, Morimasa Yagisawa). The publication reveals how coronavirus biochemistry well-established over past decades governs the morbidities of COVID-19, risk factors and therapeutic approaches.

The glycan monomer sialic acid, ubiquitous on eukaryotic cell surfaces, serves as the initial attachment point to host cells for the COVID?19 virus?SARS?CoV?2?as well as for other coronaviruses. The virus can then slide over to ACE2 for cell entry. SARS?CoV?2 spike protein attaches particularly tightly to the dense sialic acid coatings on the trillions of red blood cells (RBCs), platelets and endothelial cells in the human adult. These interlaced attachments trigger the RBC aggregation, microvascular occlusion and vascular damage underlying the oxygen deficits, blood clotting and related morbidities of severe COVID?19.

In the genetics-centric research environment of recent decades, however, most COVID?19 research ignored this older, well-established biochemistry, focusing instead on SARS?CoV?2 replication and its replication receptor, ACE2. Yet the typical human cell is coated with at most a few hundred ACE2 molecules vs. millions of virally-binding sialic acid molecules. This misdirected focus led to oversights of significant consequence, as detailed in the Viruses paper.

More broadly, disregard for the active physiological role of RBCs yields unreliable or erroneous reporting of pharmacokinetic parameters as routinely obtained for most drugs and other bioactive agents using detection in plasma, with whole blood levels being up to 30-fold higher.

Substantiation of the importance of this glycan biochemistry for COVID?19:

As detailed in the newly published paper, this glycan biochemistry is also key to disentangling controversies that have arisen over the efficacy of certain generic COVID?19 treatment agents, one of which competitively binds to several sites on SARS?CoV?2 spike protein, and the safety of spike protein-based COVID?19 vaccines.

The paper further considers how an appreciation of the related active physiological role of RBCs, the most abundant cells in the human body, can elucidate the microvascular underpinnings of other health conditions, including cardiovascular disease, and therapeutic opportunities to address them.

Contact: David Scheim, corresponding author ? [email protected]

 

Photo - https://mma.prnewswire.com/media/2392947/TrialSite_News_1.jpg
Photo - https://mma.prnewswire.com/media/2392946/TrialSite_News_2.jpg
Logo - https://mma.prnewswire.com/media/2392207/TSN_Logo.jpg 


These press releases may also interest you

at 18:15
Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024....

at 18:00
In recognition of Mother's Day on May 12th, Denny's Canada is delighted to announce that they have partnered with Women's Health Collective Canada (WHCC) to host a special fundraiser. From May 7th to 12th, in participating stores across Canada, $2...

at 17:41
Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JAMA Cardiology of two-year echocardiographic data from its REDUCE LAP-HF II randomized clinical trial of the Corvia® Atrial...

at 17:09
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for...

at 16:50
More than 12,600 people rallied together this weekend for BMO Walk so Kids Can Talk, in support of Kids Help Phone ? raising $3.7 million and counting for its #FeelOutLoud campaign....

at 16:50
Quest Diagnostics Incorporated , a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside...



News published on and distributed by: